Clinical Trials On-Line - Physican: Leslie Popplewell

The following is a list of available studies directed by Leslie Popplewell, MD

Search results: 4 Clinical trial(s) found (Page 1 of 1 )

Click here to generate a printer-friendly view

09052

P.I.:

Leslie Popplewell, MD

(Industrial)

Title:

An Open Label Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leukemias.

Click here for

Full Eligibility Criteria

08088

P.I.:

Leslie Popplewell, MD

(Industrial)

Title:

An Open-Label , Single-Arm Phase II Study of RAD001 in Patients with Refractory Mantle Cell Lymphoma

Click here for

Full Eligibility Criteria

08046

P.I.:

Leslie Popplewell, MD

(Cooperative Group)

Title:

CIBMTR: 07-REV; Evaluation of Lenalidomide as Maintenance Therapy Post Allogenic Hematopoietic Cell Transplantation for High Risk Multiple Myeloma

Click here for

Full Eligibility Criteria

07131

P.I.:	Leslie Popplewell, MD	(Institutional)
Title:	Obtaining Leukapheresed Peripheral Blood Mononuclear Cells from Mantle Cell Lymphoma Patients in Remission for Use in T Cell Program

City of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.

City of Hope has been named one of "America's Best Hospitals" in cancer and urology by U.S. News & World Report. Read more here...

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.

We subscribe to the HONcode of the Healthcare on the Net Foundation.

City of Hope

Page Title

Global Navigation